Abbisko Therapeutics presents six research advances at AACR 2026 meeting

• Abbisko Therapeutics, Abbisko Cayman unit, presented six preclinical and translational research posters at AACR 2026 held April 17-22 in San Diego.
• Presentation highlighted pan-KRAS inhibitor ABSK211, with data supporting monotherapy activity across multiple KRAS mutations.
• Abbisko Therapeutics also showcased ABK-EGFR-1 targeting EGFR C797S resistance, with preclinical results indicating CNS penetration.
• Update included ABSK061 FGFR2/3 program, with ctDNA analyses pointing to on-target FGFR2 kinase-domain mutations as common acquired resistance in gastric cancer and cholangiocarcinoma.
• Company flagged ABSK211 as in IND-enabling studies, with ABSK061 in Phase II for gastric cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbisko Cayman Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260423-12116924), on April 23, 2026, and is solely responsible for the information contained therein.